856250-49-2 Usage
Uses
Used in Medicinal Chemistry:
2-BENZYL-4-CHLORO-5-TRIFLUOROMETHANESULFONYLOXY-3(2H)-PYRIDAZINONE is used as a pharmaceutical candidate for its potential to exhibit pharmacological activities. Its complex structure allows for the possibility of interacting with biological targets, making it a valuable compound for the development of new drugs.
Used as a Synthetic Intermediate in Organic Chemistry:
Due to the presence of the chlorine and trifluoromethanesulfonyloxy groups, 2-BENZYL-4-CHLORO-5-TRIFLUOROMETHANESULFONYLOXY-3(2H)-PYRIDAZINONE can be utilized as a synthetic intermediate. This allows for further chemical modifications and the synthesis of a variety of related compounds with potential applications in different fields.
Further research and studies are necessary to fully understand the chemical and biological properties of 2-BENZYL-4-CHLORO-5-TRIFLUOROMETHANESULFONYLOXY-3(2H)-PYRIDAZINONE and to explore its potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 856250-49-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,6,2,5 and 0 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 856250-49:
(8*8)+(7*5)+(6*6)+(5*2)+(4*5)+(3*0)+(2*4)+(1*9)=182
182 % 10 = 2
So 856250-49-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H8ClF3N2O4S/c13-10-9(22-23(20,21)12(14,15)16)6-17-18(11(10)19)7-8-4-2-1-3-5-8/h1-6H,7H2
856250-49-2Relevant academic research and scientific papers
Azabicyclic heterocycles as cannabinoid receptor modulators
-
Page/Page column 115, (2008/06/13)
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.
